Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of FHND1002 in Healthy Volunteers
NCT06782958Phase 1Enrolling by invitation
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FHND1002 in amyotrophic lateral sclerosis (ALS) (10 arms), sponsored by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration at 4 weeks, Time to Peak Plasma Concentration at 4 weeks and 9 more. Started Jul 2024; status: enrolling by invitation.
02
Drugs
FHND1002
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06782958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782958.